These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27755534)

  • 1. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Zaaijer LH; van Doorn HC; Mourits MJ; van Beurden M; de Hullu JA; Adank MA; van Lonkhuijzen LR; Vasen HF; Slangen BF; Gaarenstroom KN; Zweemer RP; Vencken PM; Seynaeve C; Kriege M
    Br J Cancer; 2016 Nov; 115(10):1174-1178. PubMed ID: 27755534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
    Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
    Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
    PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
    Girardi F; Barnes DR; Barrowdale D; Frost D; Brady AF; Miller C; Henderson A; Donaldson A; Murray A; Brewer C; Pottinger C; Evans DG; Eccles D; ; Lalloo F; Gregory H; Cook J; Eason J; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Tischkowitz M; Rogers MT; Porteous ME; Morrison PJ; Eeles R; Davidson R; Snape K; Easton DF; Antoniou AC
    Genet Med; 2018 Dec; 20(12):1575-1582. PubMed ID: 29565421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
    Lorusso D; Cirillo F; Mancini M; Spatti GB; Grijuela B; Ditto A; Raspagliesi F
    Oncology; 2013; 85(2):122-7. PubMed ID: 23941904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
    Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
    Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
    Vencken PMLH; Kriege M; Hoogwerf D; Beugelink S; van der Burg MEL; Hooning MJ; Berns EM; Jager A; Collée M; Burger CW; Seynaeve C
    Ann Oncol; 2011 Jun; 22(6):1346-1352. PubMed ID: 21228333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
    Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; ; ; Collonge-Rame MA; Cook J; Daly MB; Davidson R; de la Hoya M; de Putter R; Delnatte C; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Eeles R; Ejlertsen B; Engel C; Evans DG; Faivre L; Foretova L; Fostira F; Friedlander M; Friedman E; Frost D; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Giraud S; Glendon G; Godwin AK; Goldgar DE; González-Neira A; Greene MH; Gschwantler-Kaulich D; Hahnen E; Hamann U; Hanson H; Hentschel J; Hogervorst FBL; Hooning MJ; Horvath J; Hu C; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Izquierdo A; Jakubowska A; James PA; Janavicius R; John EM; Joseph V; Karlan BY; Kast K; Koudijs M; Kruse TA; Kwong A; Laitman Y; Lasset C; Lazaro C; Lester J; Lesueur F; Liljegren A; Loud JT; Lubiński J; Mai PL; Manoukian S; Mari V; Mebirouk N; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller A; Montagna M; Mouret-Fourme E; Mukherjee S; Mulligan AM; Nathanson KL; Neuhausen SL; Nevanlinna H; Niederacher D; Nielsen FC; Nikitina-Zake L; Noguès C; Olah E; Olopade OI; Ong KR; O'Shaughnessy-Kirwan A; Osorio A; Ott CE; Papi L; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Peterlongo P; Pfeiler G; Phillips KA; Prajzendanc K; Pujana MA; Radice P; Ramser J; Ramus SJ; Rantala J; Rennert G; Risch HA; Robson M; Rønlund K; Salani R; Schuster H; Senter L; Shah PD; Sharma P; Side LE; Singer CF; Slavin TP; Soucy P; Southey MC; Spurdle AB; Steinemann D; Steinsnyder Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Thull DL; Tischkowitz M; Tognazzo S; Toland AE; Trainer AH; Tung N; van Engelen K; van Rensburg EJ; Vega A; Vierstraete J; Wagner G; Walker L; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Yadav S; Yang X; Yannoukakos D; Zimbalatti D; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC;
    Genet Med; 2020 Oct; 22(10):1653-1666. PubMed ID: 32665703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    Fong A; Cass I; John C; Gillen J; Moore KM; Gangi A; Walsh C; Li AJ; Rimel BJ; Karlan BY; Amersi F
    Am Surg; 2020 Oct; 86(10):1243-1247. PubMed ID: 33106023
    [No Abstract]   [Full Text] [Related]  

  • 14. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
    Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.
    Yuan H; Xiu L; Li N; Li Y; Wu L; Yao H
    J Gynecol Oncol; 2024 Jul; 35(4):e51. PubMed ID: 38246184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    Xu K; Yang S; Zhao Y
    Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.